Search Within

Population Sciences Research Program

  1. "Nursing"
  2. "Bone Marrow Transplant"
  3. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (5)
Groups
  1. Bone Marrow Transplant (24)
  2. Center for Hematologic Malignancies (24)
  3. Department of Medicine (24)
  4. Executive Committee, Center for Hematologic Malignancies (24)
  5. Hematologic Malignancies, Division of (24)
  6. Nursing (24)

More Groups

People
  1. Anas Younes (15)
  2. Craig Sauter (15)
  3. Maria Palomba (15)
  4. Alison Moskowitz (12)
  5. Andrew Zelenetz (12)
  6. Ariela Noy (12)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (2)
  4. 2020 (2)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (13)
  2. Clinical Cancer Research (2)
  3. Clinical Lymphoma, Myeloma and Leukemia (2)
  4. Hematological Oncology (2)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Blood Advances (1)

More Publications

Publishers
  1. American Society of Hematology (14)
  2. Elsevier Inc. (3)
  3. American Association for Cancer Research (2)
  4. Elsevier Science, Inc. (2)
  5. Wiley Blackwell (2)
  6. Ferrata Storti Foundation (1)

Results (24)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Thirty day resource utilization after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J.; Sauter, C. S.; Duck, E.; Halton, E.; Batlevi, C. W.; Palomba, M. L.; Younes, A.; Geyer, M. B.; Smith, E.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Resource utilization within 30 days of car T cells for hematologic malignancies
    Meeting Abstract

    Shah, G.; Park, J.; Sauter, C.; Duck, E.; Halton, E.; Batlevi, C.; Palomba, M. L.; Younes, A.; Geyer, M.; Smith, E.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  • Resource utilization early after chimeric antigen receptor (CAR) T cell infusion for hematologic malignancies
    Meeting Abstract

    Shah, G. L.; Park, J. H.; Sauter, C. S.; Duck, E.; Halton, E.; Palomba, M. L.; Batlevi, C. L.; Younes, A.; Geyer, M. B.; Smith, E. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schòˆder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save